Intravenous Colistin Versus Intravenous Colistin Plus Nebulized Colistin in VAP Due MDR Acinetobacter Baumannii

Phase 3b Randomized Double Blind Controled Placebo Comparative Trial of Intravenous Colistin vs Intravenous Colistin Plus Nebulized Colistin in Patients With Ventilator-associated Pneumonia (VAP) Due Multiresistant Acinetobacter Baumanii

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00645723

Enrollment

Registered

2008-03-28

Start date

2008-04-30

Completion date

2011-04-30

Last updated

2009-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cross Infection, Pneumonia, Bacterial

Keywords

Acinetobacter baumanii, Ventilator-associated pneumonia

Brief summary

Compare the clinical efficiency evaluated by the treatment of the intravenous colistin plus inhaled colistin opposite to the treatment with colistin intravenous plus inhaled saline solution in patients with VAP due to baumannii carbapenems resistant.

Detailed description

Interventions

DRUGColistin

intravenous colistin and nebulized colistin

DRUGColistin and saline solution

intravenous colistin and nebulized saline solution

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnose of VAP due A. baumannii or A. baumannii and another microorganism carbapenems resistant. * Clinical Pulmonary Infection Score (CPIS) \> 6

Exclusion criteria

* Allergy to colistin. * Asthma * Shock status * Diagnose of VAP due A. baumannii colistin resistant.

Design outcomes

Primary

Measure	Time frame
Compare the clinical efficiency evaluated by the treatment of the intravenous colistin plus inhaled colistin opposite to the treatment with colistin intravenous plus inhaled saline solution in patients with VAP due to baumannii carbapenems resistant	14 days

Countries

Spain

Contacts

Primary ContactJosé Garnacho, MD

jose.garnacho.sspa@juntadeandalucia.es34-95-501-2235

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026